{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:50Z","timestamp":1786981490967,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11060-018-2743-6","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T10:10:19Z","timestamp":1515492619000},"page":"665-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules"],"prefix":"10.1007","volume":"137","author":[{"given":"Sara","family":"Mariotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-8597","authenticated-orcid":false,"given":"Salvatore","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"2743_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","volume":"132","author":"ZA Corbin","year":"2017","unstructured":"Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S (2017) Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S\u00e9zary Syndrome. J Neurooncol 132:439\u2013446. https:\/\/doi.org\/10.1007\/s11060-017-2389-9","journal-title":"J Neurooncol"},{"key":"2743_CR2","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812\u20131821. https:\/\/doi.org\/10.1056\/NEJMoa1002965","journal-title":"N Engl J Med"},{"key":"2743_CR3","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jamadermatol.2017.3593","volume":"153","author":"DJ Lewis","year":"2017","unstructured":"Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M (2017) Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results. JAMA Dermatol 153:1302\u20131306. https:\/\/doi.org\/10.1001\/jamadermatol.2017.3593","journal-title":"JAMA Dermatol"},{"key":"2743_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM et al (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555\u2013566. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"2743_CR5","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1038\/bcj.2015.7","volume":"5","author":"S Mariotto","year":"2015","unstructured":"Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S (2015) Brentuximab vedotin: axonal microtubule\u2019s Apollyon. Blood Cancer J 5:e343. https:\/\/doi.org\/10.1038\/bcj.2015.7","journal-title":"Blood Cancer J"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2743-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2743-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2743-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T10:53:20Z","timestamp":1524740000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2743-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2743"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2743-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]}}}